These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3815389)

  • 1. Long-term influence of levodopa on bone mass and growth hormone in postmenopausal women with Parkinson's disease.
    Rico H; Vazquez A; Cabranes JA; Cantizano L; Hernandez ER; Krisnik I; Varela de Seijas E
    Clin Neuropharmacol; 1987; 10(1):87-91. PubMed ID: 3815389
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
    Galea-Debono A; Jenner P; Marsden CD; Parkes JD; Tarsy D; Walters J
    J Neurol Neurosurg Psychiatry; 1977 Feb; 40(2):162-7. PubMed ID: 864480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: Growth-hormone responses in Parkinson's disease.
    Parkes JD; Debono AG; Marsden CD
    Lancet; 1976 Feb; 1(7957):483-4. PubMed ID: 55746
    [No Abstract]   [Full Text] [Related]  

  • 4. Protein intake and treatment of Parkinson's disease with levodopa.
    Mena I; Cotzias GC
    N Engl J Med; 1975 Jan; 292(4):181-4. PubMed ID: 1109209
    [No Abstract]   [Full Text] [Related]  

  • 5. Levodopa for the treatment of Parkinson's disease.
    Lewitt PA
    N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
    Vogel HP; Ketsche R
    J Neurol; 1986 Jun; 233(3):149-52. PubMed ID: 3088217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of human somatotropin in levodopa-treated patients with Parkinsonism.
    Papavasiliou PS; McDowell FH; Rosal V; Miller ST
    Arch Neurol; 1979 Oct; 36(10):624-6. PubMed ID: 485891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe ataxic polyneuropathy associated with chronic levodopa use in Parkinson's disease.
    Kimber T; Blumbergs P; Thompson P
    Parkinsonism Relat Disord; 2013 Sep; 19(9):847-9. PubMed ID: 23746939
    [No Abstract]   [Full Text] [Related]  

  • 9. Estrogens and the pathophysiology of Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1989 Mar; 45(1-2):119-22. PubMed ID: 2714937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease and long-term levodopa therapy.
    Bergmann KJ; Mendoza MR; Yahr MD
    Adv Neurol; 1987; 45():463-7. PubMed ID: 3103389
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin.
    Cotzias GC; Papavasiliou PS; Ginos JZ
    Res Publ Assoc Res Nerv Ment Dis; 1976; 55():305-15. PubMed ID: 1005904
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa in the treatment of Parkinson's disease.
    Lloyd KG
    Prim Care; 1977 Sep; 4(3):541-60. PubMed ID: 264229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing epidemiology of Parkinson's disease: predicted effects of levodopa treatment.
    Marttila RJ; Rinne UK
    Acta Neurol Scand; 1979 Mar; 59(2-3):80-7. PubMed ID: 452843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of chronic levodopa therapy in Parkinson's disease.
    Battistin L; Bracco F; Saladini M
    J Neural Transm Suppl; 1986; 22():201-7. PubMed ID: 3465871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa efficacy and pathological basis of Parkinson syndrome.
    Rajput AH; Rozdilsky B; Rajput A; Ang L
    Clin Neuropharmacol; 1990 Dec; 13(6):553-8. PubMed ID: 2276120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endocrinological studies on Parkinson's disease (author's transl)].
    Yamamoto M; Kito S; Itoga E; Kishida T; Kamiya K
    Rinsho Shinkeigaku; 1979 Jul; 19(7):413-22. PubMed ID: 115632
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa-nonresponsive Lewy body parkinsonism: clinicopathologic study of two cases.
    Mark MH; Sage JI; Dickson DW; Schwarz KO; Duvoisin RC
    Neurology; 1992 Jul; 42(7):1323-7. PubMed ID: 1620341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.
    Frey KA
    Ann Neurol; 2001 Mar; 49(3):285-7. PubMed ID: 11261500
    [No Abstract]   [Full Text] [Related]  

  • 20. Human growth hormone response to levodopa. Relation to menopause, depression, and plasma dopa concentration.
    Sachar EJ; Altman N; Gruen PH; Glassman A; Halpern FS; Sassin J
    Arch Gen Psychiatry; 1975 Apr; 32(4):502-3. PubMed ID: 1119901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.